Arch Biopartners Inc.

ACHFF

CA03938C1041

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 15:32:25 17/07/2024 BST			5-day change	1st Jan Change
1.16 ^USD	-2.53%		-4.92%	+3.90%

06-27	Arch Biopartners Up More Than 2% After Announcing GMP Manufacturing Of Cilastatin Drug Product	MT
06-27	Arch Biopartners Inc. Announces GMP Manufacturing of Cilastatin Drug Product	CI

Arch Biopartners Inc. announced that it has received CAD 0.5 million in funding

January 28, 2019

On January 29, 2019, Arch Biopartners Inc. (OTCPK:ACHF.F) closed the transaction. TSX Venture Exchange has accepted for filing documentation. The transaction included participation from one placee.

Latest news about Arch Biopartners Inc.

Arch Biopartners Up More Than 2% After Announcing GMP Manufacturing Of Cilastatin Drug Product	06-27	MT
Arch Biopartners Inc. Announces GMP Manufacturing of Cilastatin Drug Product	06-27	CI
Arch Biopartners Obtains University of Calgary Ethics Approval to Proceed with Phase II Trial	06-18	MT
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)	06-18	CI
Arch Biopartners Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	05-31	CI
Arch Biopartners Says St. Michael's Hospital Joins Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-AKI	04-16	MT
Arch Biopartners Brief: Says St. Michael's Hospital Joins Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury	04-16	MT
Arch Biopartners Inc. Announces St. Michael's Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury	04-16	CI
Arch Biopartners Says University Health Network Joining Phase II Trial of LSALT Peptide	04-03	MT
Anesthesia Clinical Trials Unit Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated-Acute Kidney Injury	04-03	CI
Arch Biopartners Adds Three Clinical Sites in Turkey For Phase II Trial for LSALT Peptide	04-02	MT
Arch Biopartners Adds Three New Clinical Sites into the Phase Ii Trial for Lsalt Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury	04-02	CI
Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ Inflammation	03-18	MT
Arch Biopartners Clinical Team Publishes Data from Phase II Trial for Lsalt Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with Sars-Cov-2	03-18	CI
Arch Biopartners Says University of Calgary Joins Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated AKI	03-15	MT
University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury	03-15	CI
Arch Biopartners Announces Dosing Of Patient In Phase II Trial For LSALT Peptide	03-07	MT
Arch Biopartners Inc. Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated-Acute Kidney Injury	03-07	CI
Arch Biopartners Receives Health Canada Approval to Conduct Phase II Trial for Lsalt Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury	03-01	CI
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase Ii Cardiac Surgery Associated-Acute Kidney Injury Trial for Lsalt Peptide	03-01	CI
Arch Biopartners Receives Permission from U.S. FDA to Proceed with Phase II Acute Kidney Injury Trial	03-01	CI
Arch Biopartners Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	02-29	CI
Arch Biopartners on Pre-IND Meeting With FDA to Repurpose Cilastatin as New Treatment to Prevent Acute Kidney Injury	02-27	MT
Arch Biopartners Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	01-28	CI
Arch Biopartners Inc.(TSXV:ARCH) added to S&P/TSX Venture Composite Index	01-22	CI

Arch Biopartners Inc. is a portfolio-based biotechnology company focused on the development of technologies that have the potential to make a medical or commercial impact. The Company is focused on the clinical development of its drug platform in targeting dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver and kidneys. Its lead drug candidate is LSALT Peptide (Metablok). LSALT Peptide is developed for targeting organ inflammation often experienced in hospitalized COVID-19 patients. It focuses on therapeutic development of LSALT Peptide and other DPEP-1 targeting drug candidates for new indications where inflammation of the lungs, liver and kidneys is an unmet problem. It has additional technology platforms in its portfolio including AB569, which focuses on preventing antibiotic resistant bacterial infections; Borg, which is a peptide-solid surface interface, and MetaMx, which is a synthetic molecule that target brain tumor initiating cells and invasive glioma cells.

Sector

Biotechnology & Medical Research

Calendar

26/08/2024 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

1.19

Average target price

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ARCH BIOPARTNERS INC.	+3.90%	76.46M
MODERNA, INC.	+24.18%	47.96B
IQVIA HOLDINGS INC.	+0.32%	42.45B
LONZA GROUP AG	+43.96%	41.47B
ALNYLAM PHARMACEUTICALS, INC.	+26.11%	31.6B
ICON PUBLIC LIMITED COMPANY	+20.39%	28.63B
CELLTRION, INC.	-4.47%	28.03B
UNITED THERAPEUTICS CORPORATION	+51.69%	14.56B
MEDPACE HOLDINGS, INC.	+44.52%	14.14B
BIO-TECHNE CORPORATION	+2.13%	12.58B

Other Biotechnology & Medical Research